Qiagen (NYSE:QGEN) Issues Earnings Results, Beats Estimates By $0.01 EPS

Qiagen (NYSE:QGEN) issued its quarterly earnings results on Wednesday. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.01, Zacks reports. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. Qiagen updated its Q1 2025 guidance to 0.500- EPS and its FY 2025 guidance to 2.280- EPS.

Qiagen Stock Performance

QGEN stock traded up $0.40 during midday trading on Wednesday, reaching $43.76. 1,533,236 shares of the company were exchanged, compared to its average volume of 1,163,455. The business has a 50-day moving average price of $43.78 and a two-hundred day moving average price of $43.25. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The firm has a market capitalization of $9.71 billion, a price-to-earnings ratio of 109.09, a price-to-earnings-growth ratio of 3.10 and a beta of 0.36. Qiagen has a one year low of $40.15 and a one year high of $49.30.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price on the stock. in a research report on Thursday, October 17th. Jefferies Financial Group reiterated a “buy” rating and set a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $46.67 price target (down from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $50.07.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.